Oppenheimer Issues Positive Forecast for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price

Corbus Pharmaceuticals (NASDAQ:CRBP) had its price target lifted by Oppenheimer from $53.00 to $57.00 in a research report report published on Tuesday,Benzinga reports. The firm currently has an outperform rating on the biopharmaceutical company’s stock.

Several other research analysts have also issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research note on Wednesday, January 21st. Jefferies Financial Group raised shares of Corbus Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, February 18th. Finally, Royal Bank Of Canada lowered their target price on shares of Corbus Pharmaceuticals from $55.00 to $53.00 and set an “outperform” rating for the company in a report on Thursday, November 13th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $43.71.

Corbus Pharmaceuticals Price Performance

CRBP stock opened at $10.04 on Tuesday. The company has a 50 day moving average price of $8.19 and a 200 day moving average price of $10.54. Corbus Pharmaceuticals has a fifty-two week low of $4.64 and a fifty-two week high of $20.56. The stock has a market capitalization of $176.20 million, a PE ratio of -1.68 and a beta of 2.84.

Corbus Pharmaceuticals (NASDAQ:CRBP) last announced its quarterly earnings data on Monday, March 9th. The biopharmaceutical company reported ($1.25) EPS for the quarter, beating analysts’ consensus estimates of ($1.78) by $0.53. As a group, equities analysts expect that Corbus Pharmaceuticals will post -4.23 earnings per share for the current fiscal year.

Insider Buying and Selling at Corbus Pharmaceuticals

In other news, major shareholder Cormorant Asset Management, Lp sold 30,029 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $11.46, for a total value of $344,132.34. Following the completion of the transaction, the insider owned 2,344,971 shares of the company’s stock, valued at $26,873,367.66. The trade was a 1.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Dominic Smethurst sold 3,285 shares of the company’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $8.09, for a total transaction of $26,575.65. Following the completion of the sale, the insider owned 95,887 shares of the company’s stock, valued at approximately $775,725.83. This represents a 3.31% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 35,729 shares of company stock valued at $390,245 in the last three months. 4.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Corbus Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. AQR Capital Management LLC acquired a new position in shares of Corbus Pharmaceuticals in the first quarter valued at approximately $573,000. Marshall Wace LLP acquired a new stake in shares of Corbus Pharmaceuticals in the 2nd quarter valued at about $137,000. Baker Avenue Asset Management LP bought a new position in shares of Corbus Pharmaceuticals during the second quarter worth about $138,000. Bank of America Corp DE grew its holdings in shares of Corbus Pharmaceuticals by 333.6% during the second quarter. Bank of America Corp DE now owns 71,893 shares of the biopharmaceutical company’s stock worth $496,000 after buying an additional 55,314 shares in the last quarter. Finally, Assenagon Asset Management S.A. acquired a new stake in Corbus Pharmaceuticals in the 3rd quarter valued at approximately $1,080,000. 64.64% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Corbus Pharmaceuticals

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: Oppenheimer raised its price target to $57 and reiterated an “Outperform” rating, implying very large upside from current levels — a strong analyst endorsement that likely attracted buyers. Oppenheimer price target raise
• Positive Sentiment: Q4 results beat EPS estimates: Corbus reported a loss per share of ($1.25), beating consensus of ($1.78), which can be read as better-than-expected execution on expenses or operations for the quarter. Q4 press release
• Positive Sentiment: Encouraging clinical readouts: Corbus presented ESMO 2025 data showing promising efficacy for CRB‑701 in head & neck squamous cell carcinoma and cervical cancer; fuller data for both indications is expected mid‑2026, which gives a clear upcoming catalyst. ESMO / corporate update
• Positive Sentiment: Obesity program progress: 14‑day CRB‑913 data showed 2.9% weight loss with favorable GI safety and the 12‑week, 240‑patient obesity study remains on track for completion in summer 2026 — another near‑term clinical catalyst. CRB-913 data
• Neutral Sentiment: $75 million public offering closed in Q4 2025 — this materially extends runway (reducing near‑term financing risk) but also implies dilution; investors will weigh funding stability versus share dilution. Corporate update / offering
• Neutral Sentiment: Short‑interest notices in early March show reported large increases but the published figures appear to be data errors (zeros/NaN and 0 days to cover); these filings are noisy and likely not a primary driver. Short interest data
• Negative Sentiment: GAAP loss: the company reported a $20.6 million Q4 net loss — common for clinical‑stage biotechs but a reminder that future financing or milestones will matter for valuation. Earnings snapshot

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.